Trend and survival outcome in Taiwan cervical cancer patients: A population-based study

Yi-Chuan Kau, Fu-Chao Liu, Chang-Fu Kuo, Huei-Jean Huang, Allen H Li, Mei-Yun Hsieh, Huang-Ping Yu, Yi-Chuan Kau, Fu-Chao Liu, Chang-Fu Kuo, Huei-Jean Huang, Allen H Li, Mei-Yun Hsieh, Huang-Ping Yu

Abstract

Cervical cancer is one of the most common cancers in Taiwan. The aim of this study was to estimate the incidence of cervical cancer in Taiwan, the relationship between cervical cancer and previous co-morbidities, and the long-term trend of cervical cancer mortality differences in the rest of the world.This study was based on the data of cervical cancer in the National Health Insurance Research Database from 1997 to 2013, and estimated the annual prevalence and incidence of cervical cancer. Joinpoint regression analysis was used to obtain the percentage of annual incidence of cervical cancer, morbidity and survival of patients with cervical cancer by statistical regression analysis.The average annual percentage change (APC) was -7.2, indicating a decrease in the incidence of cervical cancer during the study period. The 1-year, 2-year, and 5-year mortality rates of cervical cancer are relatively stable. The average APC of mortality was higher in high Charlson comorbidity index (CCI) group.This study found that both of prevalence and incidence of cervical cancer descend in Taiwan. The incidence of cervical cancer in Taiwan is increasing with age. The sample survival rate was stable in cervical cancer patients during the study period.

Conflict of interest statement

The authors have no conflicts of interest to disclose.

Figures

Figure 1
Figure 1
Trends of crude and standardized prevalence of cervical cancer in Taiwan from 1997 to 2013.
Figure 2
Figure 2
Trends of crude and standardized incidence of cervical cancer in Taiwan from 1997 to 2013.
Figure 3
Figure 3
Geographic variation in the prevalence of cervical cancer in Taiwan in 2013.
Figure 4
Figure 4
Geographic variation in the incidence of cervical cancer in Taiwan in 2013.
Figure 5
Figure 5
Age-specific prevalence (A) and incidence (B) of cervical cancer in Taiwan in 2013.
Figure 6
Figure 6
Trends of one, 2, and 5-year survival rates of cervical cancer in Taiwan from 1997 to 2013.
Figure 7
Figure 7
Trends of one, 2, and 5-year survival rates of cervical cancer according to Charlson index ((A): Charlson index ≤ 3; (B): Charlson index ≥ 4) in Taiwan from 1997 to 2013.

References

    1. GLOBOCAN 2012 (IARC), Section of cancer surveillance. Estimated age-standardised incidence and mortality rates. Available at: Accessed February 14, 2018.
    1. Jemal A, Bray F, Center MM, et al. Global cancer statistics. CA Cancer J Clin 2011;61:69–90.
    1. GLOBOCAN 2012 (IARC), Section of cancer surveillance. Cervical cancer: Estimated incidence, mortality and prevalence worldwide in 2012. Available at: Accessed February 14, 2018).
    1. Cancer Registry Annual Report, 2013 Taiwan, Health Promotion Administration Ministry of Health and Welfare, Taiwan, 2016, p70. Available at: Accessed February 14, 2018.
    1. Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis. Lancet 2011;378:1461–84.
    1. Setoodeh R, Hakam A, Shan Y. Cerebral metastasis of cervical cancer, report of two cases and review of the literature. Int J Cli Exp Pathol 2012;5:710–4.
    1. Gustafsson L, Ponten J, Zack M, et al. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control 1997;8:755–63.
    1. Vaccarella S, Lortet-Tieulent J, Plummer M, et al. Worldwide trends in cervical cancer incidence: impact of screening against changes in disease risk factors. Eur J Cancer 2013;49:3262–73.
    1. Arbyn M, Anttila A, Jordan J, et al. European guidelines for quality assurance in cervical cancer screening. Second edition—summary document. Ann Oncol 2010;21:448–58.
    1. Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol 2010;17:1471–4.
    1. Su SY, Huang JY, Ho CC, et al. Evidence for cervical cancer mortality with screening program in Taiwan, 1981–2010: age-period-cohort model. BMC Public Health 2013;13:13.
    1. Health, United States, 2016, Table 71. Available at: Accessed February 14, 2018.
    1. NHS Cervical Screening Programme: England 2015–16. Available at: Accessed February 14, 2018.
    1. Gender Equality Committee of the Executive Yuan. Important gender statistics database: women's Pap smears and screening coverage. Available at: Accessed February 14, 2018.
    1. Chou HH, Huang HJ, Cheng HH, et al. Self-sampling HPV test in women not undergoing Pap smear for more than 5 years and factors associated with under-screening in Taiwan. J Formos Med Assoc 2016;115:1089–96.
    1. Chen W, Zheng R, Baade PD, et al. Cancer statistics in China, 2015. CA Cancer J Clin 2016;66:115–32.
    1. Howlader N, Noone AM, Krapcho M, et al. (eds). SEER Cancer statistics review, 1975-2014, National Cancer Institute. Bethesda, MD, Available at: , April 2017. Accessed February 14, 2018.
    1. Australian cancer incidence and mortality (ACIM) books: Cervical cancer. Canberra: AIHW. Australian Institute of Health and Welfare 2017. Available at: Accessed February 14, 2018.
    1. Lee FH, Wang HH. The utilization of Pap test services of women: a nationwide study in Taiwan. Cancer Nurs 2011;34:464–9.
    1. Ljubojevicb S, Skerlevb M. HPV-associated diseases. Clin Dermatol 2014;32:227–34.
    1. Medeiros LR, Rosa DD, da Rosa MI, et al. Efficacy of human papillomavirus vaccines. Int J Gynecol Cancer 2009;19:1166–76.
    1. World Health Organization. Comprehensive cervical cancer prevention and control: a healthier future for girls and women, WHO guidance note, 2013. Available at: Accessed February 14, 2018).
    1. Banura C, Mirembe FM, Katahoire AR, et al. Universal routine HPV vaccination for young girls in Uganda: a review of opportunities and potential obstacles. Infect Agent Cancer 2012;7:24.
    1. Mariani L, Pagliusi S. Vaccination and screening programs: harmonizing prevention strategies for HPV-related diseases. J Exp Clin Cancer Res 2008;27:84.
    1. Watson RA. Human papillomavirus: confronting the epidemic—an urologist's perspective. Rev Urol 2005;7:135–44.
    1. NCCN clinical practice guidelines in oncology: cervical cancer. Version 1, 2017. Accessed February 14, 2018.
    1. Marth C, Landoni F, Mahner S, et al. Cervical cancer: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(s4):72–83.
    1. Leath CA, Straughn JM, Kirby TO, et al. Predictors of outcomes for women with cervical carcinoma. Gynecol Oncol 2005;99:432–6.
    1. Diaz A, Kang J, Moore SP, et al. Association between comorbidity and participation in breast and cervical cancer screening: a systematic review and meta-analysis. Cancer Epidemiol 2017;47:7–19.
    1. Lee LJH, Chang YY, Liou SH, et al. Estimation of benefit of prevention of occupational cancer for comparative risk assessment: methods and examples. Occup Environ Med 2012;69:582–6.

Source: PubMed

スポンサーと協力者

医学的状態

薬物療法

3
購読する